Related Experiment Videos

Divalproex sodium: migraine treatment and monitoring

S D Silberstein1, L J Wilmore

  • 1Temple University School of Medicine, Philadelphia, Penn, USA.

Headache
|April 1, 1996
PubMed

Insights

Divalproex sodium effectively treats migraines, with most side effects being minor. Liver toxicity is rare, primarily in young children with complex medical conditions, suggesting clinical observation is key.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Divalproex sodium is a recognized migraine treatment.
  • Adverse drug events (ADEs) associated with divalproex sodium require careful consideration.

Purpose of the Study:

  • To evaluate the safety profile of divalproex sodium in migraine treatment.
  • To identify risk factors for serious adverse events, specifically hepatotoxicity.

Main Methods:

  • Review of clinical data and reported adverse events associated with divalproex sodium.
  • Analysis of patient demographics and co-medications in cases of hepatotoxicity.

Main Results:

  • Most adverse drug events from divalproex sodium are transient and clinically insignificant.
  • Rare instances of liver toxicity are documented in children under 10, particularly those on polypharmacy with intractable seizures and CNS disease.
  • Hepatotoxicity risk appears elevated in specific pediatric populations.

Conclusions:

  • Divalproex sodium is generally safe for migraineurs.
  • Routine monitoring of drug levels and liver function tests may not be necessary for all patients.
  • Clinical observation is the most critical tool for monitoring patient well-being and detecting potential adverse effects.

Related Concept Videos